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Objective. Quantitative analysis of the quality of nuchal translucency (NT) measurements. Methods. First-trimester combined
screeningforDownsyndromewasperformedtoallpregnantwomenattendedinourDepartmentfromOctober2003toNovember
2009.NTwasmeasuredaccordingtotheFetalMedicineFoundation(FMF)criteriaby20trainedobstetricians.Theperformanceof
NT measurements was retrospectively analyzed with regard to several quality control standards. Accuracy according to experience,
professional proﬁle, crown rump length (CRL) values, and FMF certiﬁcation was statistically tested. Results. A total of 14978 NT
measurements were assessed. (1) The mean operator-speciﬁc median NT-MoM values was 0,98. (2) Mean percentage of cases
>95th and <5th centiles were 5,0% and 4,2%, respectively. (3) Logarithmic mean and SD of the NT MoM values were 0,00 and
0,13, respectively. (4) The DR for trisomy 21 at screening time was 90,7% for a FPR of 6,7% for standard screening strategy. (5)
According to Cumulative SUM (CUSUM) ﬁgures, the performance was more acceptable in FMF-certiﬁed operators. Conclusion.
Overall, quality standards show optimal NT measurements in our unit. Operator experience, a dedicated proﬁle to fetal medicine,
CRL over 60mm, and FMF certiﬁcation have a signiﬁcant positive impact on the quality standards.
1.Introduction
In the medical ﬁeld and more precisely in prenatal ultra-
sound, the concept of quality assessment and certiﬁcation
has only recently emerged. In clinical laboratories, all tests
are regularly subjected to quality controls to determine their
reliability [1]. However, although rigid standardization of
laboratory measurements has been traditionally well estab-
lished [2, 3], clinically measurements such as ultrasound
biometries have only recently been object of interest [1, 4–8].
NT measurement has been shown to be a useful marker
for Down syndrome in the late ﬁrst trimester in both, high-
risk and low-risk populations, but only when accompanied
by targeted training and ongoing quality assessment [7]. A
continuous monitoring and scrupulous evaluations of indi-
vidual performance is likely to improve NT measurement
procedure. Although the trisomy 21 detection rate remains
a priority, this indicator cannot be used as a reliable marker
of quality, given the low prevalence of this condition. Eﬀorts
in quality assurance should include more reliable, realistic,
and individualized indicators. The aim of this study is to
quantitatively assess the quality of NT measurements over a
period of 6 years in our fetal medicine unit, testing diﬀerent
models for quality control.
2. Methods
This is a retrospective single-centre study started in October
2003, and ended in November, 2009. First trimester com-
bined screening for Down syndrome (DS) was performed to
all pregnant women attended in our Department during this
period, including maternal age, biochemistry (Pregnancy-
Associated Plasma Protein-A and free β-human Chorionic
Gonadotrophin), and NT. The maternal serum biochem-
istry was measured using the Kryptor analyzer (Brahms
Diagnostica) in a one or two-step strategy between 15 and
85mm of crown rump length (CRL) measurements. Scans
were carried out by 20 trained obstetricians, transvaginally
or transabdominally (depending on fetal and maternal
conditions). Voluson 730 and E8 (GE Medical Systems, Zipf,2 The Scientiﬁc World Journal
Austria) machines with a 5-MHz transabdominal and/or a
8-MHz transvaginal probe were used. NT was measured
according to the FMF criteria although in this series, we
include NT measurements from 40 to 85mm of CRL (we
include 40 to 44mm of CRL from cases taken before FMF
current consensus). For combined risk calculation, the SBP-
softwarewasused,acommercialaccreditednationalsoftware
widely used in our geographic area. Cytogenetic study was
recommended when combined risk index was higher than
1/270 at screening time. Outcome followup was retrieved
from our database, obtaining 96% completed cases in this
speciﬁed period. For each individual operator and overall,
the performance of the NT measurements was analyzed
with regard to the follow quality standards: (1) median NT-
multiples of the median (MoM) values and 5th and 95th
centiles, (2) percentage of cases below and above the 5th
and 95th centiles respectively, (3) logarithmic mean and
logarithmic standard deviation (SD) of the NT MoM values,
(4) performance of the screening test (detection rate-DR-
and false positive rate-FPR-), and (5) cumulative SUMs
(CUSUM) tests. CUSUMs tests display a sequential moni-
toring of a cumulative performance measure over time. After
each procedure the CUSUM tests whether the process under
scrutiny is “in control”, that is, if the process is performing
at an acceptable level. For this study, K and h values were
s e ta t0 , 2 5a n d±9,2, respectively, which corresponds to the
statistics suggested in the literature. Here, the CUSUM is
designed to detect a shift of half the standard deviation and
so K = 0.25 (K = 0.5g,w i t hg the number of standard
deviations to be detected) and the limits are set at h =± 9.2
to optimize the properties of the test [9]. CUSUM graphs
include all consecutive NT measurements during a three-
month period, excluding values over 3mm. As a reference
fortheexpectedmedianNT,theNicolaidesformulawasused
[10]. Operator-speciﬁc NT measurementaccuracyaccording
to the experience (sequential number of measurements—
ﬁrst 100 scans compared to all scans after the initial
100-), chronological period (2003–2006 versus 2007–2009),
professional proﬁle (fetal medicine dedicated or general
obstetric proﬁle), CRL values (≤60 versus >60mm), and
FMF certiﬁcation was statistically tested by Mann-Whitney
U (median NT-MoM), ANOVA (logarithmic mean), and
random eﬀects ANOVA (SD of the logarithmic NT MoM
values). The percentage of cases under and over the 5th and
95th centiles were compared by Pearson’s Chi-squared test.
3. Results
A total of 14978 NT measurements were reviewed. The mean
maternal age was 33 (range 17–45, SD 3,8) years and the
mean gestation age at scan was 11 (range 10–13,6) weeks.
Thepopulationincluded32%over35years.Downsyndrome
was identiﬁed in 54 pregnancies. Seven out of 20 operators
(35%) had a professional proﬁle dedicated to fetal medicine,
and 2 of them (10%) were FMF certiﬁed at the time of the
study. Eight operators remained from 2003 to 2009, which
represents a series of 13840 measurements (6615 in the ﬁrst
period and 7225 in the second one). Six operators performed
less than 50 NT measurements and were excluded from the
analysis. Epidemiological monitoring involved computing
ﬁve quality measurements, overall and for each operator.
(1) The mean of all operator-speciﬁc median NT-MoM
values was 0,98 (targeted value 1,0) (Table 1). Overall,
experience(comparingtheﬁrstandthesecondchronological
period), CRL > 60mm, and FMF certiﬁcation had a
signiﬁcant statistical impact improving this standard. FMF-
certiﬁed operators had a more accurate median NT-MoM
(mean of operator-speciﬁc medians of 1,00) as compared
to the noncertiﬁed sonographers (mean of medians of 0,97)
(P<0.05).Duringthestudyperiod,themedianofNT-MoM
of all operators rose signiﬁcantly, from 0,97 to 0,99 (P<
0.05). A professional proﬁle dedicated to US fetal medicine
had a tendency to improve the accuracy of measurements
although not statistically signiﬁcant.
(2) Mean percentage of cases over the 95th and below
the 5th centiles were 5,0% and 4,2%, respectively (targeted
value 5%) (Table 2). Values of CRL < 60mm and exclusive
dedication to fetal medicine had a statistical signiﬁcant
impact improving this standard.
(3) Logarithmic mean and logarithmic SD of the NT
MoM values were 0,00 and 0,13, respectively (mean and SD
expectedtobe0.00and0,08–0,13,resp.)[6](Table 3).Values
of CRL > 60mm and a dedicated proﬁle had a statistical
signiﬁcant impact improving this standard. Experience and
FMF certiﬁcation had a tendency to reduce the SD (lower
dispersion of values) although not statistically signiﬁcant.
(4) The DR for DS at screening time was 90,7% for an
FPR of 6,7% for standard screening strategy (maternal age,
NT, and biochemistry).
(5) Figures 1 and 2 show the CUSUM graph of con-
secutive NT measurements for each operator, during the
last three months, according to FMF certiﬁcation (excluding
measurements >3mm). Figure 1 shows the CUSUM graph
for the non-FMF-certiﬁed operators. Figure 2 displays the
same chart for the FMF-certiﬁed operators.
4. Discussion
Increased NT is recognized as a sensitive marker for fetal
chromosomal abnormalities. When the karyotype is normal
and the NT is enlarged, the fetus is still at increased risk
of a broad spectrum of congenital abnormalities, varying
from isolated structural defects to genetic syndromes and
neurodevelopmental delay [11, 12]. Moreover, recently, it
has been demonstrated that many of these cases are linked
with submicroscopic chromosomal abnormalities that are
typically missed by conventional karyotyping [13]. However,
NT screening displays higher variability than biochemical
markers due to a lack of automation and signiﬁcant operator
dependence. To minimize variability, international guide-
lines and quality review programs are being increasingly
recommended.
The current cross-sectional study analyzes the perfor-
mance of NT measurement with regard to several quality
standards, individually and for the overall group. Overall, in
our series, the quality standards show optimal NT measure-
ments. Moreover, data from our centre are representative of
the expected distribution of NT compared to the NicolaidesThe Scientiﬁc World Journal 3
Table 1: Multiples of the median NT values, expressed as median, 5th and 95th centiles, according to the diﬀerent criteria (operator, period,
CRL values, FMF certiﬁcation, and professional proﬁle).
MoM-NT
Median 5th centile 95th centile n
Operator
Obs 1 1,00 0,68 1,63 2.364
Obs 2 0,99 0,70 1,45 585
Obs 3 1,13 0,81 1,60 294
Obs 4 1,02 0,64 1,63 905
Obs 5 1,00 0,71 1,40 79
Obs 6 0,83 0,51 1,32 168
Obs 7 0,92 0,58 1,39 51
Obs 8 0,92 0,59 1,42 1.232
Obs 9 0,87 0,41 1,53 114
Obs 10 1,03 0,71 1,68 2.517
Obs 11 0,92 0,60 1,48 2.715
Obs 12 1,04 0,68 1,69 167
Obs 13 1,00 0,64 1,50 1.571
Obs 14 0,95 0,70 1,26 225
Period
2003–2006 0,97∗ 0,62 1,67 5560
2007–2009 0,99∗ 0,67 1,50 6623
CRL (mm)
≤60 0,96∗ 0,64 1,61 7.62
>60 1,00∗ 0,65 1,50 5.467
FMF
Certiﬁed 1,00∗ 0,67 1,47 1.719
Noncertiﬁed 0,97∗ 0,64 1,58 11.368
Proﬁle
Dedicated 0,98 0,65 1,56 11.889
Nondedicated 0,97 0,57 1,48 1.198
Overall 0,98 0,64 1,56 13.087
Obs: observer or operator.
US: scans.
FMF: Fetal Medicine Foundation.
∗P<0.05 (comparison between criteria).
reference curve. But interestingly, epidemiological monitor-
ing of NT measurements shows that there are diﬀerences
in each of the quality measures chosen, as previously pub-
lished [4, 5, 14]. For example, the use of center-speciﬁc
medians may mask important sonographer-to-sonographer
variability. A detailed analysis of the results demonstrates
that several operator (experience, dedicated professional
proﬁle,andFMFcertiﬁcation)andfetalparameters(rangeof
CRL measurements) have a signiﬁcant impact on the quality
standards. More experienced operators, particularly those
with a professional proﬁle focused on fetal medicine, CRL
over 60mm, and FMF certiﬁcation have a signiﬁcant positive
impact on the quality standards. In our series, typically
and as previously published, there was a tendency to move
the measurements closer to the median as the experience
increases, with lower dispersion of the extreme values [4,
15, 16]. CRL range has also an impact, and measurements
of NT in fetuses over 60mm length seem to be more
accurate (in terms of median MoM and logarithmic SD),
similar to previous published experiences [4]. Interestingly,
each sonographer has the opportunity to compare its own
measurements over time with the average measurements
performed at the centre. Theoretically, an increase in the
variation of NT measurements would lead to suboptimal
screeningresults.Accordingly,wefocusedonthedistribution
of these measurements in order to discover systematic
diﬀerences or changes for the individual examiner and for
the total group. Our ﬁndings show that when well-trained
examiners perform NT screening, continuous evaluation of
the distribution of the NT-MoM is a good method to assess
the quality of the center and may also be useful to identify
individual examiners deviating from the mean performance.4 The Scientiﬁc World Journal
Table 2: Distribution NT values, expressed in centiles, according to the diﬀerent criteria (operator, number of consecutive scans, period,
CRL values, FMF certiﬁcation, and professional proﬁle).
NT
≥ 95th centile ≤ 5th centile Total
n % n % n
Operator
Obs 1 186 6,7∗∗ 52 1,9∗∗ 2.776
Obs 2 17 2,5∗∗ 91 , 3 ∗∗ 669
Obs 3 20 5,7 0 0,0∗∗ 352
Obs 4 62 6,3∗∗ 38 3,9 987
Obs 5 3 2,1 1 0,7∗∗ 141
Obs 6 5 2,5 41 20,6∗∗ 199
Obs 7 40 2,8∗∗ 92 6,5∗∗ 1.407
Obs 8 8 5,1 38 24,4∗∗ 156
Obs 9 200 6,7∗∗ 43 1,4∗∗ 2.968
Obs 10 107 3,6∗∗ 190 6,4∗∗ 2.969
O b s 1 1 1 5 7 , 083 , 8 2 1 3
Obs 12 79 4,6 76 4,4 1.712
Obs 13 1 1,8 9 16,4∗∗ 55
Obs 14 1 0,4∗∗ 8 3,3 243
n◦ US
First 100 US 63 4,2 117 7,9∗ 1.486
>100 US 686 5,1 507 3,8∗ 13.492
Period
2003–2006 430 6,5∗ 328 5,0∗ 6.615
2007–2009 281 3,9∗ 172 2,4∗ 7.225
CRL (mm)
≤ 60 466 5,6∗ 381 4,6∗ 8.287
>60 283 4,2∗ 243 3,6∗ 6.691
FMF
Certiﬁed 61 3,2∗ 42 2,2∗ 1.878
Noncertiﬁed 688 5,3∗ 582 4,4∗ 13.1
Proﬁle
Dedicated 691 5,1∗ 500 3,7∗ 13.488
Nondedicated 58 3,9∗ 124 8,3∗ 1.49
Overall 749 5,0 624 4,2 14.978
Obs: observer or operator.
n◦ US: number of scans performed.
FMF: Fetal Medicine Foundation.
∗P<0.05 (comparison between criteria).
∗∗P<0.05 (comparison between obstetricians and expected binomial distribution).
Moreover, the CUSUM method has recently received atten-
tion in the medical literature owing to its simple formulation
and very intuitive representation [9]. This statistical toll
graphically presents outcomes of consecutive procedures,
estimatestheputativefactorsdiminishingtheaccuracyofthe
procedure, and assesses the competence of the operator over
a certain period of time focusing on systematic and random
errors. When applying the CUSUM method, the target, the
properties, and the control limits should be prospectively
deﬁned, less stringent at the beginning of the learning
process,andrecalculatedaccordingtostricterstandardsonce
the initial rates are achieved. In our series, these settings
are designed to detect a shift of half the SD (0,125mm),
which corresponds to the statistics suggested in the literature
[9]. As shown in the Figures 1 and 2, the performance was
more acceptable in FMF-certiﬁed operators compared with
noncertiﬁed operators. Figure 1 shows the CUSUM graph in
thenoncertiﬁedgroup,wheretheCUSUMraisesquickalarm
in almost all operators. On the contrary, Figure 2 displays
the CUSUM chart for the two-certiﬁed operators, withThe Scientiﬁc World Journal 5
Table 3: Logarithmic mean and logarithmic standard deviation (SD) of the NT MoM values, according to the diﬀerent criteria (operator,
period, CRL values, FMF certiﬁcation, and professional proﬁle).
log NT
mean SD n
Operator
Obs 1 0,01 0,12 2.364
Obs 2 0,00 0,10 585
Obs 3 0,05 0,10 294
Obs 4 0,01 0,13 905
Obs 5 0,00 0,09 79
Obs 6 −0,09 0,15 168
Obs 7 −0,04 0,11 51
Obs 8 −0,03 0,13 1.232
Obs 9 −0,07 0,18 114
Obs 10 0,02 0,12 2.517
Obs 11 −0,03 0,13 2.715
Obs 12 0,03 0,13 167
Obs 13 0,00 0,12 1.571
Obs 14 −0,02 0,08 225
Others < 50 US −0,07 0,16 100
Period
2003–2006 0,00 0,14 5.56
2007–2009 0,00 0,11 6.623
CRL (mm)∗
≤60 −0,01 0,13 7.62
>60 0,00 0,11 5.467
FMF∗∗
Certiﬁed 0,00 0,11 1.719
Noncertiﬁed −0,01 0,13 11.368
Proﬁle∗
Dedicated 0,00 0,13 11.889
Nondedicated −0,01 0,14 1.198
Overall 0,00 0,13 13.087
Obs: observer or operator.
US: scans.
FMF: Fetal Medicine Foundation.
∗P<0.05.
∗∗P<0.01.
all measurements in control during the same three-month
period. Besides its relatively simplicity and potential for
automation, the main advantages of this method include the
early detection of deviations of the measurement compared
to other standard quality control indicators. As shown in
a recent published study, CUSUM test can be used as
a prospective quality control procedure to continuously
monitor the performance of sonographers as they assess NT
in DS screening [17]. This test model shows close agree-
ment with the retrospective quality review methods on the
basis of distribution parameters currently used but with the
advantage that it can be prospectively applied, allowing for
earlier correction of deviations from target performance.
In prenatal screening policies, although the highest
achievable DR for DS remains a priority, this indicator can-
not be used as a reliable marker of quality. The image-scor-
ing methods for quality assessment have been previously in-
troduced in DS quality controls although they have been
showedpoorlyreproducible,tootimeconsuming,andthere-
fore too expensive to apply on a large scale [7, 8]. Extensive
qualitative analysis cannot be recommended for ongoing
quality control in a NT screening program [5, 8]. These
systems might be of more value during the initial training
period, or when quantitative assessment indicates the need
for further scrutiny. Epidemiological quantitative quality
monitoring is a more practical solution. The advantages6 The Scientiﬁc World Journal
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Figure 1: CUSUM graph of consecutive NT measurements for each operator for noncertiﬁed operators (during the last three months,
excluding measurements >3mm).
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Figure 2: CUSUM graph of consecutive NT measurements for each operator for certiﬁed operators (during the last three months, excluding
measurements >3mm).
of quantitative assessment are the relatively simplicity and
potential for automation. Moreover, the process of contin-
ual assessment and feedback, a well-established principle
in busi-ness and technology assessments, could be easily
adapted to aneuploidy screening in the ﬁrst trimester.
Evaluation of prenatal ultrasound measurements for pu-
rposes of quality assurance, as known from clinical laborato-
ries analyses [2, 3, 18], has only recently received attention
from the fetal medicine community [4, 6, 7, 14, 15, 19,
20]. From a historical perspective, the NT measurementThe Scientiﬁc World Journal 7
quality certiﬁcation policy from the FMF (UK) represents
the pioneer and more relevant experience in that ﬁeld [21,
22]. In the United States (US), the Society for Maternal
Fetal Medicine created the Nuchal Translucency Quality Re-
view (NTQR) Program to similarly provide education and
quality review. Evans has recently demonstrated that a rigid
oversight of NT measurements, as practiced by the UK
system, is more eﬀective than the currently practiced in the
US system [1]. Recent published papers have pointed the
eﬀect of deviation of NT measurements on the performance
ofscreening[1,8,23,24].Recently,Sahota’studyhasdemon-
strated signiﬁcant diﬀerences between center and FMF-
derivedNTMoMsandanincreaseinNTMoMmediansover
time. These authors conclude that centers should routinely
monitorthequalityofNTmeasurementsusedtoestimateDS
screening risk and should provide individualized feedback
to sonographers of their measures of central tendency and
dispersion to ensure consistent and improved performance.
Moreover, NT reference medians adopted from other pop-
ulations should be assessed and validated against a center’s
ownmeasurementdistribution[20].Otherpublicationshave
showedlesssuccessforDSscreening,probably,thisrelatedto
the lack of standardization of NT measurements [25, 26].
Traditionally, the more eﬀective quality controls have re-
lied on the biochemical screening parameters as compared
to ultrasound measurements of NT. Recent publications and
ourownexperiencedemonstratethatstrictqualitycontrolof
clinicallymeasurementssuchasNTispossibleandasreliable
as biochemistry.
5. Conclusion
Our experience in epidemiologic monitoring data shows
that the following. (1) Quality standards show optimal NT
measurements in our unit. (2) There are diﬀerences in each
of the quality measures chosen. (3) Several operator and
fetal parameters have a signiﬁcant impact on the quality
standards. (4) Despite intense and uniﬁed training for all
sonographers, NT measurements drift over time for ex-
plained and unexplained reasons. Despite appropriate train-
ing, experience, accredited certiﬁcation, and optimal quality
standards achieved, continuous monitoring and scrupulous
evaluations of individual operators is likely to lead to a
better performance of NT screening program. This study
demonstrates the importance of ongoing quality assess-
ment. Subsequently, in our centre, regular quality assur-
ance by means of simple and automatic quantitative ana-
lysis is going to be conducted at regular 6-month inter-
vals, including prospective CUSUM tool. Commitment to
ongoing quality assessment by our scientiﬁc community is
needed if early screening for DS can maintain high detection
rates and low screen-positive rates in clinical practice.
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